Grufity logoGrufity logo

Cullinan Oncology, LLC Stock Research

CGEM

10.51USD-0.05(-0.47%)Delayed

Market Summary

USD10.51-0.05
Delayed
-0.47%

CGEM Alerts

CGEM Stock Price

CGEM RSI Chart

CGEM Valuation

Market Cap

481.3M

Price/Earnings (Trailing)

4.33

Price/Sales (Trailing)

4.48

EV/EBITDA

2.15

Price/Free Cashflow

-3.77

CGEM Price/Sales (Trailing)

CGEM Profitability

EBT Margin

140.85%

Return on Equity

20.79%

Return on Assets

19.82%

Free Cashflow Yield

-26.55%

CGEM Fundamentals

CGEM Revenue

Revenue (TTM)

107.4M

Revenue Q/Q

-2.28%

CGEM Earnings

Earnings (TTM)

111.2M

Earnings Y/Y

17.63%

Earnings Q/Q

-7.97%

Price Action

52 Week Range

7.3015.89
(Low)(High)

Last 7 days

-3.2%

Last 30 days

-4.7%

Last 90 days

2.6%

Trailing 12 Months

-14.0%

CGEM Financial Health

Current Ratio

21.09

CGEM Investor Care

Shares Dilution (1Y)

3.40%

Diluted EPS (TTM)

2.38

Financials for Cullinan Oncology

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22021Q42021Q3
Revenue-45.7%10719823119.0025.00
Operating Expenses-1.3%13213412287.00-
  S&GA Expenses-5.1%40.0042.0038.0029.00-
  R&D Expenses0.5%92.0092.0085.0058.00-
EBITDA3.6%151146253--
EBITDA Margin90.8%1.41*0.74*1.20*--
Earnings Before Taxes3.6%151146155-67.48-
EBT Margin90.8%1.41*0.74*1.20*--
Net Income7.1%111104111-65.57-
Net Income Margin97.2%1.04*0.52*0.33*--
Free Cahsflow-9.4%-127-116-43.43--
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-9.1%561617667437437
  Current Assets-18.5%474582623322297
    Cash Equivalents-35.6%15624335476.0060.00
  Net PPE48.2%1.001.000.000.000.00
Liabilities-16.1%26.0031.0063.0018.0012.00
  Current Liabilities-17.0%22.0027.0062.0017.0012.00
Shareholder's Equity-8.7%535586605419425
  Retained Earnings-128.1%-47.69-20.914.00-171-158
  Additional Paid-In Capital-4.2%585611604593585
Accumulated Depreciation-0.00----
Shares Outstanding0.1%46.0046.0045.0045.0044.00
Minority InterestNaN%--0.001.000.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-8.4%-126-116-73.05-63.83-43.43
  Share Based Compensation-14.2%28.0033.0032.0027.0024.00
Cashflow From Investing-4.9%249262294-161-333
Cashflow From Financing-367.9%-25.9310.009.008.00269

Risks for CGEM

What is the probability of a big loss on CGEM?

88.8%


Probability that Cullinan Oncology stock will be more than 20% underwater in next one year

88.8%


Probability that Cullinan Oncology stock will be more than 30% underwater in next one year.

72.4%


Probability that Cullinan Oncology stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CGEM drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Cullinan Oncology was unfortunately bought at previous high price.

Drawdowns

Returns for CGEM

Cumulative Returns on CGEM

Which funds bought or sold CGEM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
unchanged
-
-95,111
442,889
-%
2023-02-28
Voya Investment Management LLC
unchanged
-
-27,435
129,565
-%
2023-02-21
MACQUARIE GROUP LTD
sold off
-
-14,000
-
-%
2023-02-15
ALLIANCEBERNSTEIN L.P.
added
5.62
-44,490
297,510
-%
2023-02-15
Tejara Capital Ltd
new
-
248,980
248,980
0.14%
2023-02-15
Metropolitan Life Insurance Co/NY
added
8.52
-2,048
20,952
-%
2023-02-15
MetLife Investment Management, LLC
reduced
-17.42
-81,716
173,284
-%
2023-02-15
Annandale Capital, LLC
unchanged
-
-22,000
106,000
0.04%
2023-02-14
Aquatic Capital Management LLC
new
-
75,000
75,000
-%
2023-02-14
SVB FINANCIAL GROUP
new
-
285,188
285,188
0.78%

1–10 of 48

Latest Funds Activity

Are funds buying CGEM calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own CGEM
No. of Funds

Cullinan Oncology News

Seeking Alpha

ORIC stock gains as H.C. Wainwright upgrades (NASDAQ:ORIC).

Seeking Alpha,
3 days ago

The News Heater

Defense World

Schedule 13G FIlings of Cullinan Oncology

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 15, 2023
jovan-embiricos morana
3.4%
1,577,440
SC 13G/A
Feb 14, 2023
biotechnology value fund l p
8.9%
4,058,854
SC 13G/A
Feb 13, 2023
chi advisors llc
7.25%
3,317,544
SC 13G/A
Feb 09, 2023
vanguard group inc
6.15%
2,812,965
SC 13G/A
Feb 03, 2023
blackrock inc.
5.5%
2,506,215
SC 13G
Feb 14, 2022
biotechnology value fund l p
6.4%
2,790,018
SC 13G/A
Feb 11, 2022
foresite capital fund v, l.p.
2.6%
1,143,006
SC 13G/A
Feb 11, 2022
chi advisors llc
5.67%
2,476,720
SC 13G
Feb 09, 2022
vanguard group inc
5.42%
2,366,808
SC 13G

CGEM Fair Value

Recent SEC filings of Cullinan Oncology

View All Filings
Date Filed Form Type Document
Mar 09, 2023
10-K
Annual Report
Mar 09, 2023
8-K
Current Report
Mar 09, 2023
S-3
S-3
Mar 09, 2023
S-8
Employee Benefits Plan
Mar 09, 2023
S-8
Employee Benefits Plan
Feb 23, 2023
4
Insider Trading
Feb 21, 2023
4
Insider Trading
Feb 21, 2023
4
Insider Trading
Feb 21, 2023
4
Insider Trading
Feb 21, 2023
4
Insider Trading

Latest Insider Trading transactions for CGEM

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-02-22
AHMED NADIM
acquired
-
-
109,000
president and ceo
2023-02-17
Michaelson Jennifer
acquired
-
-
38,500
chief development officer
2023-02-17
Trigilio Jeffrey
acquired
-
-
47,000
chief financial officer
2023-02-17
Jones Jeffrey Alan
acquired
-
-
60,000
chief medical officer
2023-02-17
SUMER JACQUELYN L
acquired
-
-
47,000
chief legal officer
2023-02-17
Baeuerle Patrick
acquired
-
-
38,500
chief scientific officer
2023-02-17
Savill Corrine
acquired
-
-
20,500
chief business officer
2023-01-19
BVF PARTNERS L P/IL
sold
-
-
-6,400,000
-
2022-12-30
Trigilio Jeffrey
acquired
1,802
8.97
201
chief financial officer
2022-11-25
Michaelson Jennifer
sold
-53,200
13.3
-4,000
see remarks

1–10 of 50

Nadim Ahmed
30
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CGEM Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]  
Revenue$ 0$ 18,943
Type of revenue [Extensible List]us-gaap:LicenseMemberus-gaap:LicenseMember
Operating expenses:  
Research and development$ 91,948$ 57,751
General and administrative40,18929,146
Total operating expenses132,13786,897
Gain on sale of Cullinan Pearl276,7850
Income (loss) from operations144,648(67,954)
Other income (expense):  
Interest income6,611477
Other income (expense), net57(8)
Net income (loss) before income taxes151,316(67,485)
Income tax expense42,1210
Net income (loss)109,195(67,485)
Net loss attributable to noncontrolling interest(2,019)(1,915)
Net income (loss) attributable to common stockholders of Cullinan111,214(65,570)
Comprehensive income (loss):  
Net income (loss)109,195(67,485)
Unrealized loss on investments(1,763)(836)
Comprehensive income (loss)107,432(68,321)
Comprehensive loss attributable to noncontrolling interest(2,019)(1,915)
Comprehensive income (loss) attributable to Cullinan$ 109,451$ (66,406)
Earnings (net loss) per share:  
Earnings Per Share, Basic$ 2.46$ (1.52)
Earnings Per Share, Diluted$ 2.38$ (1.52)
Weighted-average shares used in computing earnings (net loss) per share:  
Weighted Average Number of Shares Outstanding, Basic45,16443,077
Weighted Average Number of Shares Outstanding, Diluted46,64043,077

CGEM Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 156,152$ 59,774
Short-term investments311,140230,692
Prepaid expenses and other current assets7,1806,098
Total current assets474,472296,564
Property and equipment, net1,17477
Operating lease right-of-use assets4,1300
Other assets459147
Long-term investments80,882140,397
Total assets561,117437,185
Current liabilities:  
Accounts payable2,6603,169
Accrued expenses and other current liabilities14,1358,577
Income tax payable4,282
Operating lease liabilities, current1,421
Total current liabilities22,49811,746
Long-term liabilities:  
Lease liabilities, non-current3,590
Deferred rent065
Total liabilities26,08811,811
Commitments and contingencies (Note 12)
Stockholders' equity:  
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2022 and 2021; no shares issued and outstanding as of December 31, 2022 and 2021, respectively.
Common stock, $0.0001 par value, 150,000,000 shares authorized as of December 31, 2022 and 2021; 45,796,449 and 44,292,102 shares issued and outstanding as of December 31, 2022 and 2021, respectively.54
Additional paid-in capital585,320584,714
Accumulated other comprehensive loss(2,601)(838)
Accumulated deficit(47,695)(158,909)
Total Cullinan stockholders' equity535,029424,971
Noncontrolling interests0403
Total stockholders' equity535,029425,374
Total liabilities and stockholders' equity$ 561,117$ 437,185